Loading...

Automation And Onshoring Will Expand Life Sciences Markets Despite Headwinds

Published
24 Sep 24
Updated
06 Sep 25
AnalystConsensusTarget's Fair Value
US$104.25
34.3% undervalued intrinsic discount
10 Sep
US$68.50
Loading
1Y
-45.9%
7D
-5.2%

Author's Valuation

US$104.2534.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on06 Sep 25

With Transcat’s discount rate and future P/E both remaining essentially flat, analysts held their consensus price target steady at $104.25. What's in the News CEO Lee D.

Shared on01 May 25
Fair value Increased 12%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Decreased 7.95%

AnalystConsensusTarget has decreased profit margin from 7.2% to 5.9%.